Marshak joins the firm from Cambrex, where he was vice president and CTO. He currently serves as an adjunct associate professor at Johns Hopkins University School of Medicine and is also an advisor to PharmaFrontiers.
Marshak holds a PhD from
ChondroGene has hired David Tyler as director of product development and quality assurance.
Tyler has also held research and management positions at the Howard Hughes Medical Institute at the University of California, Berkeley; the University of California, San Francisco; and Lawrence Berkeley National Laboratory. He has a BA in biochemistry and an MS in microbiology from UC Berkley.
Israel Stein has stepped down as president and CEO of Clinical Data to become executive vice chairman, while Drew Fromkin, previously executive vice president of Clinical Data and president of the company's PGxHealth division, will now serve as president and CEO.
Stein will serve as interim CFO, replacing Mark Shooman.
Clinical Data disclosed the management changes earlier today, along with plans to spin out its investigational antidepressant drug vilazodone into a new company.
Amir Avniel has been named president and CEO of Rosetta Genomics, while Nathan Hod has joined the company's board of directors and Yoav Chelouche has been elected to serve as the new chairman of the board.
Avniel joined the company in 2000 and was formerly president, CTO, and COO.
Chelouche has been a member of the Rosetta Genomics board of directors since 2001, and is currently a managing partner at Aviv Venture Capital. He previously served as president and CEO of Scitex.
Hod co-founded DSPC, a manufacturer of chip sets for the wireless industry that was acquired by Intel in 1999.
Robert Forbes Burns has joined Celldex as CEO. Prior to joining the company, Burns was director of the office of technology licensing at the Ludwig Institute for Cancer Research.
Prior to that, Burns was commercial director at Oxford GlycoSciences, and held senior executive positions at British Biotechnology, Applied BioTechnology, Ciba-Corning Diagnostics, and Corning Diagnostics.
Burns is also a non-executive director of Lymphatix of Helsinki, Finland.
Marnie MacDonald has left Odyssey Thera, Cell-Based Assay News, a GenomeWeb News sister publication, reported last week. MacDonald was president and CEO of the company since 2002. Prior to that, MacDonald served as chief business officer for the company. Odyssey declined to comment on the reason for MacDonald's departure.
John Westwick is the current president and chief scientific officer, according to the company's website. It is unclear whether the company has named an interim or new CEO. Westwick joined Odyssey in 2003 as vice president of drug discovery.
Cell-Based Assay News also reported that Dietrich Ruehlmann has left BD Biosciences and joined New Zealand Trade & Enterprise, a government organization that assists
Ruehlmann was formerly product manager for imaging and analysis in the bioimaging systems division of BD Biosciences, based in
Sean Ekins has joined Arnold Consultancy and Technology, a pharmaceutical consulting firm based in
Frederick Schmid has joined Panacos Pharmaceuticals as senior vice president of commercial operations and business development.
Schmid most recently served as vice president of sales and marketing for virology/HIV at Roche Laboratories. Prior to that, he was executive director of HIV marketing at GlaxoSmithKline.
Schmid holds a DVM from Iowa State University College of Veterinary Medicine and an MBA from the
Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.